Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Amezalpat builds momentum with both Fast Track and Orphan Drug Designations
BRISBANE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist for the treatment of patients with hepatocellular carcinoma (HCC).
'We are thrilled to receive Fast Track designation from the FDA,' said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D of Tempest. 'This designation, following the Orphan Drug designation granted last month, reinforces the promise of amezalpat as a potential treatment option for patients affected by HCC. We look forward to working closely with the FDA and foreign regulatory agencies to develop amezalpat with the goal of bringing this promising therapy to patients.'
This is the second regulatory designation granted to amezalpat. The company announced in January that the U.S. FDA granted amezalpat with Orphan Drug Designation (ODD) following positive data across multiple key study efficacy and safety endpoints in a global randomized Phase 1b/2 clinical study evaluating amezalpat plus standard-of-care atezolizumab and bevacizumab versus atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic HCC. Notable positive outcomes of the randomized comparison include a six-month improvement in median overall survival (OS) with a hazard ratio (HR) of 0.65 for patients receiving the amezalpat combination therapy. In addition, a survival benefit from the addition of amezalpat was preserved in key sub-populations including PD-L1 negative disease, which is consistent with amezalpat's proposed mechanism of action to target both the tumor cells directly and the patient's immune system.
About Hepatocellular Carcinoma
HCC is an aggressive cancer with rising mortality and is projected to become the third leading cause of cancer death by 2030.ii Every year, more than 900,000 people worldwide are diagnosed with HCC.iii Incidence and mortality are highest in East Asia and are increasing in parts of Europe and the US.iv In the US, HCC represents the fastest-rising cause of cancer-related death. iii
Nine out of ten cases of HCC are caused by chronic liver disease, which includes chronic hepatitis B and C infection, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcohol-related liver disease (ALD) and cirrhosis resulting from these conditions.v
Even if diagnosed in the early stage, an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery.vi Early recurrence is associated with poorer prognosis and shorter survival. v,vii Tumor size, number of tumors, and portal vein invasion are associated with an increased risk of recurrence.vi
About Amezalpat
Amezalpat is an oral, small molecule, selective PPAR⍺ antagonist. Data suggests that amezalpat treats cancer by targeting tumor cells directly and by modulating immune suppressive cells and angiogenesis in the tumor microenvironment. In a global randomized phase 1b/2 study in first-line HCC patients, amezalpat in combination with atezolizumab and bevacizumab showed clinical superiority across multiple study endpoints, including overall survival in both the entire population and key subpopulations, when compared to patients receiving atezolizumab and bevacizumab alone, the standard of care. These randomized data were supported by additional positive results observed in the Phase 1 clinical trial in patients with heavily pretreated advanced solid tumors, including renal cell carcinoma and cholangiocarcinoma.
About Fast Track Designation
Fast Track designation is intended to help rapidly advance the development and review processes for promising therapeutic candidates for serious conditions that may fill an unmet medical need. Clinical programs with Fast Track designation may benefit from early and frequent communication with the FDA throughout the regulatory review process and may also be eligible for accelerated approval and priority review when relevant criteria are met.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company's website at www.tempesttx.com.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the 'Securities Act')) concerning Tempest Therapeutics, Inc. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'could', 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' and other similar expressions. All statements that are not historical facts are forward-looking statements, including any statements regarding: the design, initiation, progress, timing, scope and results of clinical trials, including the anticipated Phase 3 study for amezalpat; anticipated therapeutic benefit and regulatory development of the Company's product candidates the Company's ability to advance into a late-stage clinical company; and the Company's ability to achieve its operational plans. Forward-looking statements are based on information available to Tempest Therapeutics as of the date hereof and are not guarantees of future performance. Any factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the 'Risk Factors' section of the Company's Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2024 and other documents filed by the Company from time to time with the Securities and Exchange Commission. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics' views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.
Investor & Media Contacts:
Sylvia WheelerWheelhouse Life Science Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science Advisorsareynolds@wheelhouselsa.com
i If approved by the FDAii Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913-2921 (2014).iii World Health Organization. Liver Cancer Factsheet. Globocan. 2020. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. Last accessed: April 2023.iv Llovet, J. M., Kelley, R. K., Villanueva, A., et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021, 7(1), 6.v Office for Health Improvement & Disparities. Liver disease profiles: November 2021 update. Available at: https://www.gov.uk/government/statistics/liver-disease-profiles-november-2021-update/liver-disease-profiles-november-2021-update. Last accessed: April 2023.vi Hack SP, Spahn J, Chen M et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology. 2020 May;16(15):975-989.vii Saito A, Toyoda H, Kobayashi M et al. Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning. Modern Pathology. 2021. 34, 417-425.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Why Is Wall Street So Bearish on Plug Power? There's 1 Key Reason.
Key Points One analyst gives the stock a price target of $0.75. Profitability concerns create ongoing risks for investors. 10 stocks we like better than Plug Power › Plug Power (NASDAQ: PLUG) has captivated growth investors for decades. The company specializes in producing hydrogen fuel systems, a segment of the market that could see massive growth rates throughout the rest of this century. There should be plenty of near-term growth, too. According to research published in 2024 by Bloomberg, clean hydrogen fuel demand is expected to "skyrocket 30-fold to 16.4 million metric tons per year by 2030." But investors aren't all on board: Some Wall Street analysts remain bearish on the stock. Morgan Stanley analysts, for example, rate PLUG stock as a sell with a price target of just $0.75 -- roughly 50% below the current share price. This is the No. 1 problem with Plug Power stock today While industry forecasts call for major hydrogen fuel demand growth, the technology is still largely uncompetitive versus traditional fossil fuels, and even versus renewable sources like wind and solar. As Bloomberg's research highlights, demand growth forecasts will be very sensitive to changes in government regulations and subsidies -- two components that are critical in making hydrogen fuel economically viable. A lack of economic viability has consistently reduced demand for Plug Power's products over the decades. The company itself has often been reliant on large government subsidies to remain financially afloat. This is exactly what Wall Street analysts are worried about. Morgan Stanley's analysts have been sounding the alarm since 2023. "We see significant risk around PLUG's business model," they wrote then. "On paper, PLUG's strategy makes sense to us, but we have reduced confidence in the company's ability to execute on that strategy barring a potential dilutive capital raise." Morgan Stanley's concerns were prescient. Since that time, Plug Power has nearly doubled its share count, massively diluting shareholders in an attempt to stay financially viable. Today, the company continues to post negative net incomes quarter after quarter. The future is bright for hydrogen fuel. But Plug Power's lack of profitability continues to concern analysts, and is something investors have to watch. Should you buy stock in Plug Power right now? Before you buy stock in Plug Power, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Plug Power wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Is Wall Street So Bearish on Plug Power? There's 1 Key Reason. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
3 Serious Tesla Problems Investors Aren't Talking Enough About
Key Points Lawsuits continue to mount for Tesla and Elon Musk. There has been a flurry of executive departures from the company. Losing revenue from zero-emission credit sales is a big blow to EV makers. These 10 stocks could mint the next wave of millionaires › It's been a bumpy ride for Tesla (NASDAQ: TSLA) investors in 2025. The EV maker is feeling the heat from all angles: media, consumers, analysts, you name it. But for all the consumers leaving the brand, and the media frustrated with Elon Musk's political antics, there are a few problems that have gone unnoticed. Let's take a look at recent lawsuits, the talent exodus, and the loss of valuable zero-emissions credit sales. 1. Lawsuits keep mounting Just earlier this month, Elon Musk and Tesla were sued by shareholders who accused them of securities fraud for hiding the serious risk its self-driving vehicles posed. The proposed class action lawsuit was filed earlier this month and was a black eye after the automaker's first public test of its robotaxis in late June in Austin, Texas. These lawsuits have a wide range of driving forces, many seemingly from the actions of Musk himself. In fact, as of August 2023, Tesla was already party to over 1,750 lawsuits, a big chunk of them in China, where the company is already struggling to protect market share and profits amid a brutal price war and increased competition from domestic Chinese automakers. Also earlier this month, a federal jury found Tesla partly liable in a 2019 car crash that killed a pedestrian and left another badly injured while the automobile was on Autopilot. The jury awarded the plaintiffs $43 million in compensatory damages for pain and suffering, plus another $200 million in punitive damages. These lawsuits are certainly difficult to keep track of, but investors would be wise to remember that these lawsuits are adding up, and some can be very costly in brand image or directly through damages. 2. A concerning talent exodus Amid the flurry of negative news facing Tesla, many investors brushed off the peppering of executive departures throughout the year. But this is a talent exodus that has become, and should be, concerning to investors. Here's a look at key departures, to name a few: Omead Afshar (VP/Head of Sales and Manufacturing, North America/Europe) Milan Kovac (Head of Optimus Humanoid Robot Team) Vineet Mehta (Head of Battery Architecture) Troy Jones (VP of Sales, Service, and Delivery, North America) Pete Bannon (VP of Hardware Engineering, Chip Tech, and Dojo Supercomputer) Piero Landolfi (Director of Service, North America) Those were just a handful of high-profile executives and key personnel departing, and its leaders in key areas such as service, sales, engineering, and even the robotics team. The departures raise concerns about Tesla's leadership, operational challenges, and its current ability to remain competitive. 3. Companies in this space are losing valuable revenue To say that Tesla and some of its EV competitors are about to lose a significant revenue source is putting it lightly. That's right: Tesla, Lucid, and Rivian, among others, are about to see billions of dollars in revenue disappear seemingly overnight as U.S. policy essentially ends the zero-emission credit market. Essentially, the government formerly penalized automakers with lower average fuel economy, or those that produced more gasoline-guzzling vehicles and fewer EVs, but that is no longer. Without penalties being enforced, those companies failing to meet emissions standards are no longer incentivized to purchase zero-emission credits from EV makers to meet standards. And as the market for those zero-emission credits dried up, so too did a significant chunk of revenue for EV makers with a surplus of such credits. The National Highway Traffic Safety Administration (NHTSA) has already stopped issuing compliance letters to automakers that violate the fuel economy standards. What it all means When it rains, it pours -- at least that's how it seemed for most of Tesla's developments this year. But savvy investors would be wise to keep abreast of developments with Tesla lawsuits and its massive talent exodus, in addition to losing valuable revenue from zero-emission credits. These haven't been covered enough and raise uncertainty surrounding the EV maker. Long-term investors should try and weather the storm and stay focused on the company's business long term. But it's also fair to say Tesla is at a crossroads with its future strategy, and investors will have to revisit their investment thesis to see if they are still aligned. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $472,031!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $43,882!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $671,466!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 18, 2025 Daniel Miller has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. 3 Serious Tesla Problems Investors Aren't Talking Enough About was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Should You Buy Shopify Stock After Its Post-Earnings Pop?
Key Points Shopify's revenue growth is accelerating. The company is adding new features for AI tools, advertising, and a consumer shopping app. The stock trades at a wildly expensive valuation today. 10 stocks we like better than Shopify › Investors in Shopify (NASDAQ: SHOP) have gone on a wild ride in the last five years. The e-commerce software and payments platform saw surging growth and a meteoric rise in its stock price during the COVID-19 pandemic before crashing down to earth in 2022. Shares went from close to $170 to below $30 in less than two years. Now, the stock is rising again, hitting recent highs of over $150 after positing strong growth yet again in the second quarter of 2025. But still, Shopify shareholders remain underwater if they bought at most points in 2021. Does that mean the stock is a buy today after its recent post-earnings pop? Accelerating global growth Even though inflation has come down and consumer spending growth has slowed in the United States, Shopify's revenue growth is accelerating. It is doing so by gaining market share of e-commerce and retail spending in the United States while expanding to new markets such as Europe. Last quarter, revenue grew 31% year over year to $2.68 billion, compared to 21% growth in the year-ago period. Payment volume in Europe -- which correlates closely to revenue -- grew 42% and greatly outpaced overall sales. Why are more and more businesses such as Starbucks and Canada Goose adopting Shopify's software tools? Because of its wide breadth of products that help grow their businesses, outsourcing an important function (having your own online storefront) to a trusted third party. Not every sale is going to come from Amazon, while some companies don't want to sell on broad-based marketplaces at all. Shopify's tools help businesses process payments and grow earnings, which leads to more revenue for Shopify as it takes a cut of every transaction. This is a self-reinforcing cycle that has helped Shopify's revenue grow from well under $1 billion to $10 billion in less than 10 years, making it one of the fastest-growing businesses in the world. Expanding products and margin expansion potential Shopify is not resting on its laurels. It is building new services to grow with its customer base. This includes connections with artificial intelligence (AI) query services to help pull products from its commerce partners when users ask chatbots questions. Everything comes back to driving more sales through e-commerce websites, which has driven total payment volume on Shopify partner websites from under $1 billion in 2012 to $327 billion in the last 12 months. What's more, Shopify is now moving beyond payments for commerce partners through Shopify Campaigns, an advertising service. These campaigns can go on traditional channels such as Google or Instagram but also on the native Shop application. Shop is a mobile app from Shopify that acts as an aggregator for its e-commerce partners, similar to Amazon. This is a bold new venture in building a consumer-facing application but greatly expands Shopify's addressable market. Add everything together along with the core tailwind of its e-commerce market share gains and Shopify should be able to grow its revenue at a double-digit rate for a long while. In 2025, it expects to grow revenue between 25% and 30% compared to 2024. Right now, Shopify's operating margin is 15.4%. As a payments and software company with low overhead, increasing scale should lead to improving profit margins for Shopify in the years to come. This can help underlying earnings grow even faster than revenue. Should you buy Shopify stock? After looking through the financials, it is clear that Shopify is a great business. This is why the stock price is up 5,000% since its initial public offering (IPO) around 10 years ago. That does not necessarily make the stock a buy, though. Shopify's stock trades at a forward price-to-earnings ratio (P/E) of about 76. This metric takes the current market cap of $185 billion and divides it by consensus estimates of $1.84 per share for net income over the next 12 months. This is already factoring in Shopify's expected strong revenue and earnings growth in the coming quarters. It will be many years before this lofty P/E ratio gets down to the average level of 20 to 30 for large-cap stocks listed in the United States. At a market cap pushing $200 billion and only $10 billion in trailing revenue, Shopify stock looks overvalued, even though the business is firing on all cylinders. You should avoid buying shares of this company after its post-earnings pop. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Brett Schafer has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Shopify, and Starbucks. The Motley Fool has a disclosure policy. Should You Buy Shopify Stock After Its Post-Earnings Pop? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
